Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA E545X||endometrial adenocarcinoma||no benefit||PIK3CA inhibitor||Copanlisib||Case Reports/Case Series||Actionable||In a Phase II (NRG-GY008) trial, Aliqopa (copanlisib) was well tolerated but demonstrated limited efficacy, resulted in progressive disease in a patient with endometrioid adenocarcinoma harboring a PIK3CA E545 mutation, and progressive disease in a patient with serous endometrial adenocarcinoma harboring a PIK3CA E545 mutation (PMID: 31934607).||31934607|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03842228||Phase I||Copanlisib + Durvalumab + Olaparib||Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations||Recruiting||USA||0|
|NCT04586335||Phase I||CYH33 + Olaparib||Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.||Recruiting||USA||1|
|NCT05154487||Phase II||Alpelisib + Fulvestrant||A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer||Not yet recruiting||USA||0|